Robert Baiocchi A MD, PhD


​ 

Robert Baiocchi A MD, PhD
Assoc ProfessorCollege of Medicinebaiocchi.1@osu.edu
B404 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-685-56667Fax: (614) 292-3312
  • Leukemia Research

General Research Interest

HIV/AIDS and immune deficiency associated malignancies, Experimental therapeutics of lymphoma, Viral oncogenesis

Research Description

Our laboratory program focuses on 3 major areas of research: (1) experimental therapeutics of lymphomas (epigenetics, antibodies, vaccine/immunotherapy); (2) mechanisms of Epstein-Barr virus driven B cell transformation; and (3) clinical research involving new methods to treat immune deficient patients (HIV/AIDS, post transplantation) who develop cancer.

Transinstitutional Work

Our trans-institutional collaborative work involves our participation in the National Cancer Institutes' AIDS Malignancy Consortium (AMC) and the Blood and Bone Marrow Transplantation Clinical Trials Network (BMT CTN).  As the institutional principal investigator of the AMC at Ohio State, i help develop new treatment protocols and manage patients with HIV/AIDS associated cancers.  I am part of a working group at the BMT-CTN developing clinical trials to perform autologous and allogeneic stem cell transplantation in HIV+ patients with refractory or relapsed lymphomas.

Current Publications

  • Lustberg ME, Pelletier RP, Porcu P, Martin SI, Quinion CD, Geyer SM, Caligiuri MA, Baiocchi RAHuman Leukocyte Antigen Type and Posttransplant Lymphoproliferative Disorder.Transplantation in press 11/25/2014
  • Humphries K, Lozanski G, Baiocchi RA, Jaglowski SM, Blum K, Porcu P, Flynn J, Penza S, Benson DM, Andritsos LA, Devine SM, Hofmeister CC, Williams N, Geyer S, Hade EM, Bowers MA, Earl CT, Vaughn J, Bingman AA Phase 1 study of Vorinostat Maintenance after Autologous Transplant in High Risk Lymphoma.Leuk Lymphoma in press 1-16 9/11/2014
  • Baiocchi RADriving toward targeted therapy for LCH.Blood 124 1546-8 9/4/2014
  • Patton JT, Lustberg ME, Lozanski G, Garman SL, Towns WH, Drohan CM, Lehman A, Zhang X, Bolon B, Pan L, Kinghorn AD, Grever MR, Lucas DM, Baiocchi RAThe translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease.Oncotarget in press 6/12/2014
  • Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Hall NC, Nagar VA, Hemminger JA, Jones JA, Porcu P, Christian BA, Baiocchi RA, Maddocks KJ, Flynn JM, Devine SM, Blum KAComplete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.Cancer 120 1677-85 6/1/2014
  • Martin LK, Cordero-Nieves HM, Banasavadi-Siddegowda Y, Virk S, Barnholtz-Sloan J, Bell EH, Wojton J, Jacob NK, Chakravarti A, Nowicki MO, Wu X, Lapalombella R, Datta J, Yu B, Gordon K, Haseley A, Patton JT, Smith PL, Ryu J, Zhang X, Yan F, Alinari L, Lustberg ME, Mo X, Marcucci G, Nuovo G, Kwon CH, Byrd JC, Chiocca EA, Li C, Sif S, Jacob S, Lawler S, Kaur B, Baiocchi RAGenetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.Cancer Res 74 1752-65 3/15/2014
  • Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JCFlavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.Am J Hematol 89 19-24 1/1/2014
  • Chung J, Karkhanis V, Tae S, Yan F, Smith P, Ayers LW, Agostinelli C, Pileri S, Denis GV, Baiocchi RA, Sif SProtein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.J Biol Chem 288 35534-47 12/6/2013
  • Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JMCyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.Leuk Res 37 1195-9 10/1/2013
  • Hall NC, Ruppert AS, Jones JA, Porcu P, Baiocchi R, Christian BA, Penza S, Benson DM Jr, Flynn J, Andritsos LA, Devine SM, Blum KA, Cohen JBAssociation of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.Bone Marrow Transplant 48 1212-7 9/1/2013
  • Nicholas C, Yang J, Peters SB, Bill MA, Baiocchi RA, Yan F, Sïf S, Tae S, Gaudio E, Wu X, Grever MR, Young GS, Lesinski GBPRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.).PLoS One 8 e74710 1/1/2013
  • Shilo K, Wu X, Sharma S, Welliver M, Duan W, Villalona-Calero M, Fukuoka J, Sif S, Baiocchi R, Hitchcock CL, Zhao W, Otterson GACellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors.Diagn Pathol 8 201 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu